Depending on whether RIG-I turns out to play beneficial roles for the host or the virus, targeting this PRR with either agonists or antagonists could have impact on host restriction of viral replication, or alternatively inhibit chronic immune activation, hence affecting the immunopathogenesis and preventing the progression to immunodeficiency during chronic HIV infection. Here, RIGI is linked to Immunodeficiency.